End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.91 CNY | -2.20% | +1.14% | -17.27% |
04-25 | Jinyu Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02-27 | Taihe Technologies' Chief Financial Officer Resigns | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 63% by 2025.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.63 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.27% | 1.34B | B | ||
-19.73% | 72.39B | B+ | ||
-11.01% | 6.54B | B- | ||
+15.88% | 3.43B | B- | ||
-0.68% | 1.4B | - | ||
-2.73% | 1.26B | - | ||
-28.16% | 1.2B | C- | ||
-14.67% | 1.12B | - | ||
-5.37% | 990M | - | ||
-24.06% | 805M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600201 Stock
- Ratings Jinyu Bio-technology Co., Ltd.